Passage BIO, Inc., also known as Passage Bio (PASG), is a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic CNS (central nervous system) diseases that are caused by single gene defects and that are devastating to patients and their families. The company utilizes its suite of proprietary technologies for the development of its pipeline, which includes fully integrated gene therapy, genome editing, oligonucleotides, and small molecule approaches.
Based in the vibrant biotech hub of Philadelphia, USA, Passage Bio was founded in 2018 with the mission to provide life-transforming therapies for patients with severe CNS disorders that have unmet medical needs. The company's foundation is built on its collaboration with renowned, research-driven institutions such as the University of Pennsylvania’s Gene Therapy Program (GTP) and Penn’s Orphan Disease Center (ODC).
Passage Bio’s deep understanding of crucial disease biology and the utilization of advanced technologies enables them to precisely target the underlying genetic cause of a disease, helping to address unmet medical needs and provide treatments for patients without any carrying options. They are dedicated towards achieving their mission through patient centricity, and a culture that focuses on scientific excellence, integrity, and collaboration.
Composed of a seasoned team of gene therapy and CNS disease experts, Passage Bio is committed to spearheading research and technological innovation. Despite being a relatively young enterprise, the company has several therapeutic programs underway. Their portfolio concentrates on rare monogenic diseases, which include GM1 gangliosidosis and frontotemporal dementia, among others.
Just over two years from its inception, Passage Bio made an entry into the public market through an IPO in February 2020. Drawing attention from both investors and industry insiders, the company raised approximately $216 million at the time of its initial public offering, proving its robust potential in the biotech sector.
Passage Bio stands out for their unwavering commitment to rigorous scientific methodology and the creation of gene therapies that have the potential to drastically improve the quality of life for patients suffering from debilitating CNS disorders. With their patient-first mindset, innovative research approach, and dedicated professional team, Passage Bio has forged a path as a frontrunner in genetic medicine development for rare CNS disorders. As PASG continues to develop, it is expected to maintain its significant contributions to the field of gene therapy.